{
    "clinical_study": {
        "@rank": "148182", 
        "arm_group": [
            {
                "arm_group_label": "Tofacitinib 5 mg BID (oral) (70 subjects)", 
                "arm_group_type": "Experimental", 
                "description": "Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin at least 2 weeks following vaccination and continue for 12 weeks."
            }, 
            {
                "arm_group_label": "Placebo tofacitinib BID (oral) (70 subjects)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin at least 2 weeks following vaccination and continue for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate immune response following administration of zoster vaccine in\n      subjects with rheumatoid arthritis  who are receiving background methotrexate and initiate 5\n      mg twice daily of tofacitinib or placebo for tofacitinib at least 2 weeks following\n      vaccination."
        }, 
        "brief_title": "A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have moderate to severe rheumatoid arthritis inadequately controlled by\n             methotrexate as defined by the American College of Rheumatology (ACR) classification\n             criteria for Rheumatoid arthritis, painful and swollen joint counts and C-reactive\n             protein  (CRP).\n\n          -  Screening CRP >7 mg/L.\n\n          -  Subjects must have active disease at screening and baseline.\n\n          -  Must be at least 50 years of age or older.\n\n        Exclusion Criteria:\n\n          -  History of receiving any varicella-zoster virus vaccine\n\n          -  Receipt of any other live vaccine within 6 weeks of first dose of study treatment.\n\n          -  Subjects with current infections or history of infections.\n\n          -  History of recurrent (more than one episode) of herpes zoster or disseminated (a\n             single episode) of herpes zoster or disseminated (a single episode) of herpes\n             simplex."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147587", 
            "org_study_id": "A3921237"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tofacitinib 5 mg BID (oral) (70 subjects)", 
                "description": "5 mg twice daily of tofacitinib with background methotrexate for 12 weeks", 
                "intervention_name": "Tofacitinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo tofacitinib BID (oral) (70 subjects)", 
                "description": "Placebo tablets twice daily with background methotrexate for 12 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921237&StudyName=A%20Study%20to%20Assess%20Immune%20Response%20Following%20Zoster%20Vaccination%20to%20Subjects%20with%20Rheumatoid%20Arthritis%20Receiving%20Tofacitinib%20or%20Placebo%20with"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Immune Response Following Administration of Zoster Vaccine to Subjects With Rheumatoid Arthritis Receiving Tofacitinib (CP-690,550) Or Placebo With Background Methotrexate Treatment", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Varicella-zoster virus (VZV) antibodies as measured by an enzyme-linked immunosorbent assay (ELISA) for VZV immunoglobulin (IgG) at 6 weeks post-vaccination (Week 4 on study treatment)", 
            "safety_issue": "No", 
            "time_frame": "Visit 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147587"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "VZV-specific cell mediated immunity (CMI) to zoster vaccine as measured by interferon(IFN)-gamma enzyme-linked immunosorbent spot (ELISPOT)", 
                "measure": "Absolute number of spot-forming cells/10^6 peripheral blood mononuclear cells (PBMCs) at baseline and 2, 6 and 14 weeks following immunization (Study Day 1, Week 4 and Week 12)", 
                "safety_issue": "No", 
                "time_frame": "Visit 2, 3 and 4"
            }, 
            {
                "description": "VZV-specific cell mediated immunity (CMI) to zoster vaccine as measured by interferon(IFN)-gamma enzyme-linked immunosorbent spot (ELISPOT)", 
                "measure": "Occurrence of a >=1.5-fold increase from vaccination baseline in spot-forming cells/10^6 PMBCs at 2, 6 and 14 weeks following immunization (Study Day 1, Week 4 and Week 12)", 
                "safety_issue": "No", 
                "time_frame": "Visit 2, 3 and 4"
            }, 
            {
                "description": "VZV-specific cell mediated immunity (CMI) to zoster vaccine as measured by interferon(IFN)-gamma enzyme-linked immunosorbent spot (ELISPOT)", 
                "measure": "Fold increase from vaccination baseline in spot-forming cells/10^6 PBMCs at 2, 6 and 14 weeks following immunization (Study Day 1, Week 4 and Week 12).", 
                "safety_issue": "No", 
                "time_frame": "Visit 2, 3 and 4"
            }, 
            {
                "description": "VZV antibodies as measured by ELISA for VZV IgG", 
                "measure": "VZV-specific IgG levels at 2 weeks and 14 weeks (Study Day 1 and Week 12) following immunization.", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 and 4"
            }, 
            {
                "description": "VZV antibodies as measured by ELISA for VZV IgG", 
                "measure": "Occurrence of a >=1.5-fold increase from vaccination baseline in VZV-specific IgG levels at 2, 6 and 14 weeks following immunization (Study Day 1, Week 4 and Week 12).", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 and 4"
            }, 
            {
                "description": "VZV antibodies as measured by ELISA for VZV IgG", 
                "measure": "Fold increase from vaccination baseline in VZV-specific IgG levels at 2, 6 and 14 weeks following immunization (Study Day 1, Week 4 and Week 12).", 
                "safety_issue": "No", 
                "time_frame": "Visit 2 and 4"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}